Senior government officials, industry leaders and academics from India and the United States are said to attend the annual India-United States summit on biopharmacy and health care virtually next week.
Amitabh Kant, CEO of NITI Aayog, Alberta Bourla, CEO of Pfizer, Francis Collins, Director of the National Institutes of Health (NIH) and Janet Woodcock, Acting Commissioner of the Food and Drug Administration (FDA), are expected to address the summit . Speakers are expected to discuss areas of cooperation and emerging trends in drug discovery and development, organizers said on Friday.
Taking place against the backdrop of the Covid-19 pandemic, the 15th annual summit on June 22 is hosted by the USA India Chambers of Commerce (USAIC) based in Boston.
India will encourage research, says Kant
“The pandemic has demonstrated the need for global collaboration and partnership in drug and vaccine development, research and clinical trials, analysis of health data to deliver solutions at a faster rate.” , Kant said.
In a statement, Kant commended USAIC for bringing together global leaders of BioPharma to discuss emerging trends in drug development, research and innovation and for initiating dialogue on the potential use of the drug. data science to boost the industry.
“With a focus on sectors of the pharmaceutical industry such as vaccines, orphan drugs, biosimilars and complex generics, India is looking for ways to encourage research, to encourage collaboration between industry and universities and attract global scientific talent to strengthen its R&D ecosystem, âhe said.
Looking forward to hearing from world leaders at the USAIC summit on how to improve international collaboration to conduct high-quality, ground-breaking research and place the pharmaceutical industry among the best industries in the world, Kant said that it currently contributes 3.6% of the global pharmaceutical market, India aims to increase its share to seven percent over the next decade by creating global champions.
For the second year in a row, the annual conference is being held virtually.
âDuring the 15th Annual USAIC BioPharma & Healthcare Summit, we will have the opportunity to hear many different perspectives and engage with leaders in the healthcare ecosystem,â said Andrew Plump, President of the R&D, Takeda Pharmaceutical Company Limited and President of USAIC Biopharma & Healthcare Summit. and member of the USAIC advisory board.
âThere is growing recognition that we need to develop new ways of innovating that will require models of partnership and collaboration for industry, academia, the investment community, nonprofit and government sectors to work. together earlier in the R&D process and more significantly to accelerate our collective efforts for patients … and we need to be proactive and make the necessary investments now, âhe said.
Need for access and equity
Commending USAIC for bringing together leaders of the pharmaceutical and biotechnology industry from India and abroad, K. Vijay Raghavan, Senior Science Advisor, Government of India and USAIC Advisory Board Member said that ‘today, more than ever, there is a need to bring access and equity to cutting-edge, life-saving discoveries.
âThis can only happen if we improve collaboration, maintain standards and find ways to ensure that costs to the recipient are reasonable and ensure maximum access. “It is this combination of developing and using the best interventions and making sure they are available that is India’s goal,” he said.
“By doing so, India hopes to contribute to global access to quality biotech and pharmaceutical products, even more than it currently does,” he said.
According to Karun Rishi, president of USAIC, several thousand people from all over the world have registered for this annual summit. âAs a service to the global BioPharma community in these unprecedented times, USAIC offers free registration to its annual summit,â he said.
Observing that human suffering has been unprecedented and heartbreaking due to Covid-19, he said India suffered disproportionately during the second wave. âThe global BioPharma industry has mobilized never before seen resources to help India cope with this crisis. This summit gives us the opportunity to thank industry leaders for their timely assistance to India including Pfizer, Merck & Co, Amgen, Johnson & Johnson, Sanofi, Takeda, Biogen and many others, âsaid Rishi .
âThe benefit of the Covid-19 pandemic is that it will bring India closer to an innovation-driven economy. The future of a vibrant and healthy India rests on the evolution of its biopharmaceutical industry towards research and innovation. We believe that India’s top leaders understand this and are committed to working in this direction, âhe said.
The summit brings a strong participation of the US government. Among them are Francis Collins, Director of NIH and Janet Woodcock, Acting Commissioner, US FDA.
The participation of Pfizer CEO Albert Bourla, Amgen CEO Robert Bradway and Biogen President Stelios Papadopoulos, as well as global R&D leaders from Janssen, Takeda, Sanofi, Amgen, Biogen, UCB and several other companies demonstrate the willingness of global innovative biopharmaceutical companies to work with India, he said.